Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022 SOUTH SAN FRANCISCO, Calif. , May 19, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today that as anticipated it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons pursuant to the

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business Update Tricida continued to execute on

SOUTH SAN FRANCISCO, Calif. , May 03, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2022 financial results after the close of market on Tuesday, May 10, 2022 . Tricida will host a conference call and webcast at 4:30 pm Eastern Time to

SOUTH SAN FRANCISCO, Calif. , April 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today that it will present at the 21 st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 10:30 am Pacific Time / 1:30 pm Eastern Time .

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. , March 29, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives.

SOUTH SAN FRANCISCO, Calif. , March 16, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close of market on Tuesday, March 29, 2022 . Tricida will host a conference call and webcast at 4:30 pm

SOUTH SAN FRANCISCO, Calif. , March 02, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney

SOUTH SAN FRANCISCO, Calif. , March 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney

SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 am PT / 10:30 am ET . Gerrit Klaerner , Ph.D., Tricida’s Founder, President